Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[How to select and use urate lowering agents for hyperuricemia]

H Yamanaka1

  • 1Institute of Rheumatology, Tokyo Women's Medical College.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intervention of somatic mutational events in vivo by a germline defect at the adenine phosphoribosyltransferase locus.

Human genetics·1997
Same author

[Effects of alcohol on urate metabolism].

Nihon rinsho. Japanese journal of clinical medicine·1997
Same author

[A case report of renal cell carcinoma with bilateral adrenal metastases].

Hinyokika kiyo. Acta urologica Japonica·1997
Same author

An asymptomatic germline missense base substitution in the hypoxanthine phosphoribosyltransferase (HPRT) gene that reduces the amount of enzyme in humans.

Human genetics·1997
Same author

Generation and molecular characterisation of monoclonal IgG4 rheumatoid factor from a patient with rheumatoid arthritis.

Annals of the rheumatic diseases·1997
Same author

[Alcohol ingestion and hyperuricemia].

Nihon rinsho. Japanese journal of clinical medicine·1996
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Urate-lowering medications like uricosuric agents and allopurinol treat hyperuricemia. Choosing the right agent based on uric acid excretion, and starting with low doses, helps prevent gouty arthritis.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Nephrology

Context:

  • Hyperuricemia management requires careful selection of urate-lowering agents.
  • Two main classes exist: uricosuric agents and allopurinol.
  • Phenotyping patients based on urate excretion is crucial for effective treatment.

Purpose:

  • To guide the selection of urate-lowering therapy based on patient phenotype.
  • To outline strategies for preventing complications associated with hyperuricemia treatment.

Summary:

  • Uricosuric agents are recommended for urate underexcretion, while allopurinol is for overproduction.
  • The urinary uric acid/creatinine ratio aids in determining the appropriate treatment strategy.
  • Initiating therapy with minimal doses and maintaining serum uric acid levels between 5.0-6.4 mg/dl minimizes gouty arthritis risk.

Related Experiment Videos

Impact:

  • Optimized treatment selection for hyperuricemia patients.
  • Reduced incidence of urinary urate stones and potential liver damage.
  • Decreased risk of gouty arthritis during initial treatment phases.